SLC9A1 and breast carcinoma: It has been shown that chemical inhibition of NHE1 along with paclitaxel therapy resulted in a significant decrease in the invasive and migratory behaviour of breast cancer cells, indicating the potential of using NHE1 as a novel co-adjuvant target in combination with paclitaxel therapy to enhance the efficacy of breast cancer treatment [15].